MX2024006948A - Terapia combinada que comprende un inhibidor de pkc y un inhibidor de c-met. - Google Patents
Terapia combinada que comprende un inhibidor de pkc y un inhibidor de c-met.Info
- Publication number
- MX2024006948A MX2024006948A MX2024006948A MX2024006948A MX2024006948A MX 2024006948 A MX2024006948 A MX 2024006948A MX 2024006948 A MX2024006948 A MX 2024006948A MX 2024006948 A MX2024006948 A MX 2024006948A MX 2024006948 A MX2024006948 A MX 2024006948A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitor
- combined therapy
- therapy including
- pkc
- met
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163286345P | 2021-12-06 | 2021-12-06 | |
| US202263317573P | 2022-03-08 | 2022-03-08 | |
| US202263370056P | 2022-08-01 | 2022-08-01 | |
| PCT/US2022/080928 WO2023107894A1 (en) | 2021-12-06 | 2022-12-05 | Combination therapy comprising a pkc inhibitor and a c-met inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024006948A true MX2024006948A (es) | 2024-08-06 |
Family
ID=86731264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024006948A MX2024006948A (es) | 2021-12-06 | 2022-12-05 | Terapia combinada que comprende un inhibidor de pkc y un inhibidor de c-met. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240335440A1 (https=) |
| EP (1) | EP4444303A4 (https=) |
| JP (1) | JP2024542831A (https=) |
| AU (1) | AU2022407330A1 (https=) |
| CA (1) | CA3239676A1 (https=) |
| IL (1) | IL313361A (https=) |
| MX (1) | MX2024006948A (https=) |
| WO (1) | WO2023107894A1 (https=) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014174478A1 (en) * | 2013-04-26 | 2014-10-30 | Novartis Ag | Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor |
| CA2955676A1 (en) * | 2014-08-25 | 2016-03-03 | Pfizer Inc. | Combination of a pd-1 antagonist and an alk inhibitor for treating cancer |
| US11413284B2 (en) * | 2017-09-12 | 2022-08-16 | Novartis Ag | Protein kinase C inhibitors for treatment of uveal melanoma |
| AU2020386903A1 (en) * | 2019-11-18 | 2022-06-09 | Ideaya Biosciences, Inc. | Dosing regimens for a protein kinase C inhibitor |
| JP2023541011A (ja) * | 2020-09-08 | 2023-09-27 | イデアヤ、バイオサイエンシズ、インコーポレイテッド | 医薬組み合わせおよび腫瘍治療 |
-
2022
- 2022-12-05 JP JP2024533880A patent/JP2024542831A/ja active Pending
- 2022-12-05 MX MX2024006948A patent/MX2024006948A/es unknown
- 2022-12-05 WO PCT/US2022/080928 patent/WO2023107894A1/en not_active Ceased
- 2022-12-05 US US18/715,927 patent/US20240335440A1/en active Pending
- 2022-12-05 EP EP22905269.1A patent/EP4444303A4/en active Pending
- 2022-12-05 IL IL313361A patent/IL313361A/en unknown
- 2022-12-05 CA CA3239676A patent/CA3239676A1/en active Pending
- 2022-12-05 AU AU2022407330A patent/AU2022407330A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3239676A1 (en) | 2023-06-15 |
| EP4444303A4 (en) | 2025-11-26 |
| EP4444303A1 (en) | 2024-10-16 |
| AU2022407330A1 (en) | 2024-07-04 |
| US20240335440A1 (en) | 2024-10-10 |
| WO2023107894A1 (en) | 2023-06-15 |
| JP2024542831A (ja) | 2024-11-15 |
| IL313361A (en) | 2024-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023000735A (es) | Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer. | |
| MX2022007376A (es) | Fluoroalqull-oxadiazoles y sus usos. | |
| CO2021015614A2 (es) | Terapias de combinación que comprenden inhibidores de apremilast y tyk2 | |
| JOP20220263A1 (ar) | مثبط ret بلوري | |
| MX2022012992A (es) | Inhibidores de kif18a para el tratamiento de enfermedades neoplasicas. | |
| CR20220545A (es) | ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRA EL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2) | |
| EA202092154A1 (ru) | Комбинированная терапия | |
| BR112023025916A2 (pt) | Combinação de um inibidor de braf e um inibidor de mek, uso de uma combinação, método para o tratamento ou profilaxia de câncer, composições farmacêuticas e invenção | |
| MX374749B (es) | Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tratar cancer. | |
| CO2024007225A2 (es) | Tratamiento de trastornos hepáticos con un agonista del thr-β | |
| GEAP202416612A (en) | Tricyclic urea compounds as jak2 v617f inhibitors | |
| MX2025010799A (es) | Inhibidores de acilsulfonamida para lisina acetiltransferasa 6a (kat6a) | |
| BR112023002733A2 (pt) | Composições e métodos de fabricação de células t | |
| MX2022000845A (es) | Compuestos inhibidores. | |
| MX2025011869A (es) | Terapia de combinacion que comprende un inhibidor de parg y un inhibidor de topoisomerasa para tratar cancer | |
| BR112022017491A2 (pt) | Método para tratar indivíduos resistentes ao inibidor idh1 | |
| MX2024006948A (es) | Terapia combinada que comprende un inhibidor de pkc y un inhibidor de c-met. | |
| MX2024015041A (es) | Fitusiran para el tratamiento de la hemofilia a y b | |
| MX2021015403A (es) | Terapia de combinacion que comprende un conjugado de anticuerpo-farmaco anti-cd19 y un inhibidor de pi3k o un agente secundario. | |
| MX2022014133A (es) | Tratamiento para cancer de mama usando tratamientos conjuntos que comprenden gdc-9545 y un inhibidor de cdk4/6. | |
| MX2022012632A (es) | Uso de inhibidores del bromodominio para el tratamiento de la enfermedad de huntington. | |
| BR112022010733A2 (pt) | Métodos para tratar dor | |
| BR112022013673A2 (pt) | Inibidores de ahr e seus usos | |
| MX2022011844A (es) | Terapia combinada con un inhibidor de idh mutante. | |
| MX2022001450A (es) | Metodo de tratamiento del cancer. |